Despite effective screening methods for cervical cancer, many women do not have access or are not screened in a timely manner which results in delayed diagnosis and higher rates of advanced disease with lower survival rates. In recent years, immunotherapy has emerged as a new frontline treatment option that improves outcomes in women with PD-L1 positive advanced cervical cancer. In this activity you will learn about one patient’s journey with advanced cervical cancer, including her symptoms, the importance of biomarker testing, and her experience with immunotherapy.
- Host: Ritu Salani, MD, MBA
Need a quick tutorial on cervical cancer screening, biomarker testing, and immunotherapy for advanced disease? Sharpen your clinical skills here.
Available credits: 0.50
Provided by RMEI Medical Education, LLC
Oncology, OB/GYN, and Women’s Health clinicians
Upon completion of this activity, participants should be better able to:
Apply guideline-concordant cervical cancer screening strategies in vulnerable and high-risk patient populations
Utilize appropriate biomarker testing strategies in persistent, recurrent, or metastatic cervical cancer
Integrate immunotherapeutic strategies in persistent, recurrent, or metastatic cervical cancer according to approved guidelines and indications
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Ritu Salani, MD, MBA, has relevant financial relationships with Eisai, Genentech, GSK, Immunogen, Merck, Regeneron, Seagen (Consultant).
All of the relevant financial relationships listed for this individual have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at email@example.com.
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100 AMAZON GIFT CARD!*
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
Supported by an independent medical education grant from Merck.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers1.00 program credit
Samuel J. Klempner, MD
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers1.00 program credit
Samuel J. Klempner, MD
Roy F. Chemaly, MD, MPH